J.P. Morgan Sticks to Its Buy Rating for Omada Health, Inc. (OMDA)
J.P. Morgan analyst Destiny Jackson maintained a Buy rating on Omada Health, Inc. on October 24 and set a price target of $31.00. The company’s shares closed yesterday at $26.42.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Currently, the analyst consensus on Omada Health, Inc. is a Strong Buy with an average price target of $27.43, a 3.82% upside from current levels. In a report released on October 22, Barclays also maintained a Buy rating on the stock with a $28.00 price target.
The company has a one-year high of $28.40 and a one-year low of $14.14. Currently, Omada Health, Inc. has an average volume of 424.5K.
Read More on OMDA:
Disclaimer & DisclosureReport an Issue
- Omada Health appoints Tsang as Chief Medical Officer
- Omada Health price target raised to $28 from $24 at Barclays
- Omada Health’s Surge in App Downloads and GLP-1 Care Track Expansion Justify Buy Rating
- Omada Health added to ‘Tactical Outperform’ list at Evercore ISI
- Omada Health launches “Meal Map” AI-powered nutrition tool
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.